FDA: Eylea Approval Expanded to Include Diabetic Retinopathy

Share this content:
FDA: Eylea Approval Expanded to Include Diabetic Retinopathy
FDA: Eylea Approval Expanded to Include Diabetic Retinopathy

WEDNESDAY, March 25, 2015 (HealthDay News) -- U.S. Food and Drug Administration approval of Eylea (aflibercept) has been expanded to treat diabetic retinopathy among people with diabetic macular edema, the agency said Wednesday in a news release.

The injected drug Eylea is intended to be used in tandem with appropriate therapies to control blood glucose, blood pressure, and cholesterol, the FDA said.

The drug's safety and effectiveness were evaluated in clinical studies involving 679 people. The most common side effects included bleeding of the conjunctiva, eye pain, cataracts, floaters, and increased intraocular pressure.

Eylea was first approved in 2012 to treat wet age-related macular degeneration, and also was sanctioned to treat diabetic macular edema and macular edema secondary to retinal vein occlusions.

The drug is marketed by Regeneron Pharmaceuticals, based in Tarrytown, N.Y.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Dermatologists' Rx for Antibiotics Dropped From 2008 to 2016

Dermatologists' Rx for Antibiotics Dropped From 2008 to ...

However, rising use of antibiotics after dermatologic surgical visits is concerning

Coronary Artery Calcium May Help Predict CVD in South Asians

Coronary Artery Calcium May Help Predict CVD in ...

CAC incidence similar in South Asian men versus white, black, Latino men; higher than Chinese

High Levels of Activity, Motor Ability Linked to Better Cognition

High Levels of Activity, Motor Ability Linked to ...

Findings seen in older adults; independent correlations remained for those with Alzheimer disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »